A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Takeda
Perspective Therapeutics
Novartis
VM Oncology, LLC
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
Incyte Corporation
Incyte Corporation
Instituto do Cancer do Estado de São Paulo
Turnstone Biologics, Corp.
Sotio Biotech Inc.
Symphogen A/S
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Rain Oncology Inc
Xencor, Inc.
Ascentage Pharma Group Inc.
Incyte Corporation
AbbVie
MacroGenics
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Centre Hospitalier Universitaire de Nice
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Valerio Therapeutics
Valerio Therapeutics
University of Chicago